Why Merck (MRK) Shares Are Trading Lower Today [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
its partner Eisai, announced that a late-stage clinical trial for a kidney cancer treatment failed to meet its primary goals. The Phase 3 LITESPARK-012 trial was evaluating a three-drug combination involving Merck's drug Welireg for patients newly diagnosed with advanced renal cell carcinoma, the most common type of kidney cancer. The results showed the treatment did not significantly delay tumor progression or extend survival compared to the current standard of care. This outcome was a notable setback for Merck's oncology pipeline, particularly as the company prepares for the eventual patent expiration of its blockbuster drug, Keytruda. The news appeared to heighten investor concerns about the company's future profit outlook. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Merck? Access our full analysis report here, it's free What Is The Market Telling Us Merck's shares are not very
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Kelun-Biotech Announces Three Clinical Study Results Selected for Oral Presentations at 2026 ASCO Annual Meeting [TheStreet.com]TheStreet.com
- Merck Weighs New HIV Approval Against Mixed Oncology Trial Results [Yahoo! Finance]Yahoo! Finance
- FDA Approves Merck's Once-Daily IDVYNSO™ (doravirine/islatravir) [Yahoo! Finance]Yahoo! Finance
- FDA Approves Merck’s Once-Daily IDVYNSO™ (doravirine/islatravir)Business Wire
- Merck Rises 11% YTD: Should Investors Buy, Sell or Hold the Stock? [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 2/3/26 - Beat
MRK
Sec Filings
- 4/8/26 - Form ARS
- 4/8/26 - Form DEFA14A
- 4/8/26 - Form DEF
- MRK's page on the SEC website